Skip to main content

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.

Publication ,  Journal Article
Vahdat, LT; Schmid, P; Forero-Torres, A; Blackwell, K; Telli, ML; Melisko, M; Möbus, V; Cortes, J; Montero, AJ; Ma, C; Nanda, R; Wright, GS ...
Published in: NPJ Breast Cancer
May 20, 2021

The METRIC study (NCT#0199733) explored a novel antibody-drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1-14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

NPJ Breast Cancer

DOI

ISSN

2374-4677

Publication Date

May 20, 2021

Volume

7

Issue

1

Start / End Page

57

Location

United States

Related Subject Headings

  • 4202 Epidemiology
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vahdat, L. T., Schmid, P., Forero-Torres, A., Blackwell, K., Telli, M. L., Melisko, M., … Yardley, D. A. (2021). Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. NPJ Breast Cancer, 7(1), 57. https://doi.org/10.1038/s41523-021-00244-6
Vahdat, Linda T., Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, et al. “Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.NPJ Breast Cancer 7, no. 1 (May 20, 2021): 57. https://doi.org/10.1038/s41523-021-00244-6.
Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. NPJ Breast Cancer. 2021 May 20;7(1):57.
Vahdat, Linda T., et al. “Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.NPJ Breast Cancer, vol. 7, no. 1, May 2021, p. 57. Pubmed, doi:10.1038/s41523-021-00244-6.
Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J, Montero AJ, Ma C, Nanda R, Wright GS, He Y, Hawthorne T, Bagley RG, Halim A-B, Turner CD, Yardley DA. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. NPJ Breast Cancer. 2021 May 20;7(1):57.

Published In

NPJ Breast Cancer

DOI

ISSN

2374-4677

Publication Date

May 20, 2021

Volume

7

Issue

1

Start / End Page

57

Location

United States

Related Subject Headings

  • 4202 Epidemiology
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences